ArticleMicrobial cell factories2025
Screening of Red Sea- and Mediterranean Sea-derived Actinomycetes for Antimicrobial and Antitumor activities: LC-ESI-HRMS-based Metabolomics Study.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Anticancer natural products from the Middle East and North Africa: biodiversity, mechanisms, and translational challenges.Frontiers in oncology · 2026Review
- Comprehensive Genome Analysis of Two BioactiveBiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In reply to the critical requirement for new anti-infective and anticancer agents, this study explores aquatic actinomycetes as a favorable source of naturally occurring bioactive compounds. Using metabolomics and dereplication analysis, we investigated the chemical profiles of promising eight actinobacterial isolates out of seventy-eight actinomycetes isolated from the Red Sea and the Mediterranean Sea. The eight isolates (6, 10, 12, 35, 42, 43, 45, and 48) demonstrated cytotoxic activity against the breast adenocarcinoma (MCF-7) cell line and broad-spectrum antimicrobial activity against Gram-negative and Gram-positive microbes. Isolate 10 exhibited the broadest antibacterial activity, while isolates 42, 43, and 45 showed moderate to weak cytotoxic potential. Genetic identification via 16S rRNA sequencing classified seven isolates as Streptomyces sp. and one as Brevibacterium sp. Multivariate data analysis (MVDA) of the high-resolution mass spectrometry (HRMS) data identified isolate 10 as an outlier, rich in diverse secondary metabolites. Dereplication revealed numerous metabolites with potential antimicrobial and anticancer activity, confirmed by NMR data highlighting their complex chemical profiles. These findings underscore the effectiveness of integrating metabolomics and bioassays to uncover unique bioactive products from aquatic actinobacteria, creating a foundation for further development of novel antimicrobial and antitumor medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.